Pfizer And Ionis’s Antisense Cholesterol Candidate Sparks Safety Worries
Concerns Despite Phase IIb Win
Executive Summary
Increases in liver enzymes and fat could dampen approval prospects despite vupanorsen meeting its mid-stage primary endpoint, some analysts have said.
You may also be interested in...
ANGPTL3 Road Has Some Potholes As Pfizer Sends Vupanorsen Back To Ionis
The decision followed the November 2021 announcement that while a Phase IIb study hit its primary endpoint, the magnitude of benefit was too small and adverse event rate too high.
Regeneron's Evkeeza Approved For Ultra-Rare Genetic High Cholesterol – And Priced To Match
Evkeeza is the first ANGPTL3 approved by the FDA; Regeneron scientists discovered the angiopoetin gene family.